Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C
- 11 September 2009
- journal article
- review article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 44 (10) , 1009-1015
Abstract
Hepatitis C virus (HCV) is a single-stranded RNA virus known for its high genetic variability owing to the lack of a proofreading mechanism of its RNA dependent RNA polymerase. Until now, numerous studies have been undertaken to clarify the correlation between pretreatment HCV genetic variability and the therapeutic response. Even with the recent combination therapy of peginterferon plus ribavirin for chronic hepatitis C, viral response is variable, and only half of treated patients could clear the virus [sustained viral response (SVR)]. In this review, the contribution of viral genetic variability affecting the treatment outcome is discussed according to each HCV genomic region.Keywords
This publication has 87 references indexed in Scilit:
- A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological responseJournal of Medical Virology, 2009
- Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapyWorld Journal of Gastroenterology, 2009
- Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing AntibodiesJournal of Virology, 2008
- Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factorsHepatology, 2008
- Hepatitis C virus envelope components alter localization of hepatocyte tight junction–associated proteins and promote occludin retention in the endoplasmic reticulum†Hepatology, 2008
- Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment ResponsesJournal of Virology, 2008
- Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy†Hepatology, 2008
- Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to TherapyJournal of Virology, 2007
- Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin MonotherapyGastroenterology, 2007
- Mutations within the Hepatitis C Virus Genotype 1b E2-PePHD Domain Do Not Correlate with Treatment OutcomeJournal of Clinical Microbiology, 2005